Cargando…
Immunotherapy of triple-negative breast cancer with cathepsin D-targeting antibodies
BACKGROUND: Triple-negative breast cancer (TNBC) treatment is currently restricted to chemotherapy. Hence, tumor-specific molecular targets and/or alternative therapeutic strategies for TNBC are urgently needed. Immunotherapy is emerging as an exciting treatment option for TNBC patients. The asparti...
Ejemplares similares
-
SPARC in cancer‐associated fibroblasts is an independent poor prognostic factor in non‐metastatic triple‐negative breast cancer and exhibits pro‐tumor activity
por: Alcaraz, Lindsay B., et al.
Publicado: (2022) -
A 9-kDa matricellular SPARC fragment released by cathepsin D exhibits pro-tumor activity in the triple-negative breast cancer microenvironment
por: Alcaraz, Lindsay B, et al.
Publicado: (2021) -
Co-Expression of Androgen Receptor and Cathepsin D Defines a Triple-Negative Breast Cancer Subgroup with Poorer Overall Survival
por: Mansouri, Hanane, et al.
Publicado: (2020) -
High PTPN13 expression in high grade serous ovarian carcinoma is associated with a better patient outcome
por: D’Hondt, Véronique, et al.
Publicado: (2017) -
BRCA1 Promoter Hypermethylation is Associated with Good Prognosis and Chemosensitivity in Triple-Negative Breast Cancer
por: Jacot, William, et al.
Publicado: (2020)